The value of autoantibody seroconversion was also highlighted by Giannicola et al., who found that ANA, ENA, or anti-smooth muscle antibody positivity after nivolumab initiation was associated with a higher risk of irAEs in patients with non-small cell lung cancer (Giannicola et al., 2019). Here, BTG3 is linked to non-small cell lung carcinoma.